Persistence of MHC DR nonexpression on swine cells by introduction of a mutated MHC class II transactivator gene: A comparison with the effect induced by antisense RNA

Journal of Clinical Immunology

Volumn 24, Issue 1, 2004, Pages 97-106

  Ou, Qishui ^a,c   Lin, Lin ^a   Huang, Lidong ^a   Chen, Fuxiang ^a   Wu, Kegui ^c   Lu, Peihua ^a   Zhang, Jingwu ^b   Chou, Kuang Yen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Acute cellular rejection; Class II transactivator; Dominant negative mutant; Swine leukocyte antigen; Xenogeneic organ transplantation

Indexed keywords

COMPLEMENTARY DNA; COMPLEMENTARY RNA; HLA DR ANTIGEN; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SWINE LEUKOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; GENE EXPRESSION; GENE MUTATION; GRAFT REJECTION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE REACTION; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE; T LYMPHOCYTE; XENOTRANSPLANTATION;

ANIMALS; DOWN-REGULATION; HLA-DR ANTIGENS; HUMANS; MUTATION; NUCLEAR PROTEINS; RNA, ANTISENSE; SEQUENCE ANALYSIS, PROTEIN; SEQUENCE ANALYSIS, RNA; SWINE; T-LYMPHOCYTES; TRANS-ACTIVATORS; TRANSFECTION;

EID: 1642278669     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOCI.0000018068.37899.6d     Document Type: Article

References (32)

1. Schmoeckel M, Nollert G, White Fabre: Transgenic human decay accelerating factor makes normal pigs function as a concordant species. Transplantation 59:1325-1330, 1995.
2. Kaiser J: Cloned pigs may help overcome rejection. Science 295:25-26, 2002
3. Yamada K, Sachs D: Dersimonian H. Human anti-porcine xenogeneic T cell response, Evidence for allelic specificity of mixed leucocyte reaction and for both direct and indirect pathways of recognition. J Immunol 155:5249-5256, 1995
4. Murphy B, Auchincloss H, Caroenter CB, et al.: T cell recognition of xeno-MHC peptide during concordant xenograft rejection. Transplantation 61:1133-1140, 1996
5. Reith W, Mach B: The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19:331-373, 2001
6. Steimle V, Otten LA, Zufferey M, et al.: Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (bare lymphocyte syndrome). Cell 75:135-146, 1993
7. Scholl T, Mahanta SK, Strominger JL: Specific complex formation between the type II bare lymphocyte syndrome-associated transactivator CIITA and RFX5. Proc Natl Acad Sci USA 94:6330-6334, 1997
8. Riley JL, Westerheide SD, Price JA, et al.: Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity 2:533-543, 1995
9. Moreno CS, Roger EM, Brown JA, et al.: Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex. J Immunol 158:5841-5848, 1997
10. Fontes JD, Kanazawa S, Nekrep N, Peterlin BM: The class II transactivator CIITA is a transcriptional integrator. Microbes Infect 1:1863-869, 1999
11. Dziembovska M, Fondancehe MC, Vedrenne J, et al.: Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency. Immunogenetics 53:821, 2002
12. Martin BK, Chin KC, Olsen JC, et al.: Induction of MHC class I expression by the MHC class transactivator CIITA. Immunity 6:591-600, 1997
13. Chang CH, Flavell RA: Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 181:765-767, 1995
14. Masternak K, Muhlethaler-Mottet A, Villard J, et al.: CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Gene Dev 14:1156-1166, 2000
15. Gobin SJ, van Zutfen M, Westerheide SD, Boss JM, van den Elsen: The MHC-specific enhanceosome and its role in MHC class I and beta (2) -microglobulin gene transactivation. J Immunol 167:5175-5184, 2001
16. Nagarajan UM, Lochamy J, Chen X, Beresford GW, Nilson R, Jenson PE, Boss JM: Class II transactivator is required for maximal expression of HLA-DO in B cells. J Immunol 168:1780-1786, 2002
17. Steimle V, Siegrist CA, Mottet A, et al.: Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science 265:106-109, 1994
18. Gobin S, Peijnenburg A, Keijser V, et al.: Site α is crucial for two routes of IFN-γ-induced MHC class I transactivation: The ISRE-mediated route and a novel pathway involving CIITA. Immunity 6:601-610, 1997
19. Panelli MC, Wang E, Shen S, et al.: IFN-γ gene transfer of an EMT6 tumor that is poor responsive to IFN-γ stimulation: Increase in tumor immunogeneity is accompanied by induction of a mouse class II transactivator and class MHC. Cancer Immunol Immunother 42:99-107, 1996
20. Yazawa T, Kamma H, Fujiwara M, et al.: Lack of class II transactivator cause severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 187:191-199, 1999
21. + T cells, but not after IFN-gamma stimulation. J Immunol 165:734-742, 2000
22. Chin KC, Li G, Ting JPY: Activation and transdominat suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants. J Immunol 159:2789-2794, 1997
23. Zhou H, Su HS, Zhang XD, et al.: CIITA-dependent and independent class II MHC expression revealed by a dominant negative mutant. J Immunol 158:4741-4749, 1997
24. Yun S, Gustafsson K, Fabre JW: Suppression of MHC class II expression by human class II transactivator constructs lacking the N-terminal domain. Int Immunol 9:1545-1553, 1997
25. Bontron S, Catherine U, Bernard M, et al.: Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a function selection strategy. Mol Cell Biol 17:4249-4259, 1997
26. Yun S, Gustafsson K, Fabre JW: Suppression of human anti-porcine T cell immune response by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain. Transplantation 66:103-111, 1998
27. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. J Biol Chem 89:5547-5551, 1992
28. Baron V, Schnappinger D, Heibl V, et al.: Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes. Proc Natl Acad Sci USA 96:1013-1018, 1997
29. Bach FH, Winkler H, Ferran C, Hancock WW: Delayed xenograft rejection. Immunol Today 17:379-384, 1996
30. Xie J, Chen FX, Li NL, Shen BH, Hong J, Chou KY: Human T cells response to swine leucocyte antigens through direct recognition. Shanghai J Immunol 20:136-139, 2000
31. Sataka M, Kawagishi N, Moller E: Direct activation of human responder T cells by porcine stimulator cells leads to T cell proliferation and cytotoxic T cell development. Xenotransplantation 3:149-154, 1996
32. Dorling A, Binnes R, Lechler RI: Cellular xenoresponses: Although vigorous, direct human T cell anti-pig primary xenoresponses are significantly weaker than equivalent alloresponses. Xenotransplantation 3:147, 1996